Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Search
Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis
Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis
Swine
Swine
Simple and straight to the source: tips for ileitis control
Simple and straight to the source: tips for ileitis control
Salmonella in pigs, pork and people
Salmonella in pigs, pork and people
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Inadvertent self-injection: The risk associated with oil-based vaccines
Inadvertent self-injection: The risk associated with oil-based vaccines
A versatile solution for PCV2 and PRRS protection
A versatile solution for PCV2 and PRRS protection
Twenty years of controlling Lawsonia intracellularis
Twenty years of controlling Lawsonia intracellularis
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Ingelvac CircoFLEX®: The most successful animal health vaccine of all time is also a very versatile product
Ingelvac CircoFLEX®: The most successful animal health vaccine of all time is also a very versatile product
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Reducing PCV2 Viremia in Neonatal Pigs Through Sow Mass Vaccination in an Unstable Herd
Reducing PCV2 Viremia in Neonatal Pigs Through Sow Mass Vaccination in an Unstable Herd
Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot
• Boehringer Ingelheim Animal Health Canada Inc. launches a unique vaccine combination that protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv) in one shot
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
What large scale economic analyses are saying about Enterisol™ Ileitis
What large scale economic analyses are saying about Enterisol™ Ileitis
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Does your PRRS vaccine have sufficient “horsepower?”
Does your PRRS vaccine have sufficient “horsepower?”
Vaccine protection against different PRRS virus strains
Vaccine protection against different PRRS virus strains